Evaluation Of tuberculin skin test and booster effect in hemodialysis patients


Masomeh Alimagham 1 , * , Saied Aminiafshar 1 , Latif Gachkar 1 , Kamran Sharafim 1 , Mohammad Farahbakhsh 1

1 Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, IR Iran

How to Cite: Alimagham M, Aminiafshar S, Gachkar L, Sharafim K, Farahbakhsh M. Evaluation Of tuberculin skin test and booster effect in hemodialysis patients, Arch Clin Infect Dis. Online ahead of Print ; 1(1):-.


Archives of Clinical Infectious Diseases: 1 (1)
Article Type: Research Article


Background: Tuberculosis is an endemic disease in Iran which may occur more frequently among hemodialysis patients. We have evaluated tuberculin skin test (TST) in hemodialysis patients in a university hospital in 2003-2004.

Sixty-seven hemodialyis patients were enrolled for tuberculin skin tests. Indurations were measured 48-72 hours after the injection and then on the 7th day. Those with indurations less than 5mm in TST1 were introduced for TST2.

Results: Of 67 patients, 18(26.9%) had indurations of less than 5mm in TST1 and were introduce for TST2 among whom 7 (39%) had an induration measured less than 5mm. Of 18 cases, 11 (61%) were revealed to have booster effect that represent a ratio of 16% of all studied hemodialysis patients in our study.

Conclusion: It seems that the second TST is a better indicator of infectivity in hemodialysis patients, especially for patients who require repeated or annual estimation for M. tuberculosis infection.

Full Text

Full text is available in PDF

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.